Clinical Trial Update: Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

View source ↗

Summary

Completed study P04085 evaluated Caelyx (liposomal doxorubicin) in ovarian cancer, focusing on prevention and treatment of infusion reactions and palmar-plantar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ovarian Neoplasms | Status: COMPLETED | Results posted: 2010-06-22